News Acomplia Zimulti

News Acomplia Zimulti (Rimonabant -Rip)

Subscribe via Email

Researchers Convinced Variety of Drugs Needed to Beat Body’s Stockpiling of Fat

A growing number of scientists and doctors have become convinced Acomplia (rimonabant) that overcoming the body’s imperative to stockpile fat will require an assortment of drugs, mixed and matched in various combinations, and that many patients will be taking these cocktails for years — perhaps for life — along with dieting and exercising, according to a front-page report in The Washington Post Acomplia (rimonabant) .

“ It’s commonplace to use multiple drugs for complex diseases,” said Arthur Frank, an obesity expert at George Washington University. “Most people with Acomplia (rimonabant)  AIDS take combination drugs. Most people with cancer take combinations of drugs. Most people with heart disease use a combination of drugs. That’s probably what we’ll have to get to with the management of obesity.”

The Post reports that while the drug closest to FDA approva Acomplia (rimonabant) , rimonabant, blocks a pathway in the brain that produces the craving for food, three other drugs have undergone fairly extensive testing.

Acomplia (rimonabant) Regeneron Pharmaceuticals Inc.’s Axokine suppresses appetite. A small British biotech company, Alizyme PLC, is developing ATL-962, which blocks fat absorption. And Ortho-McNeil Pharmaceutical’s epilepsy drug, Topamax, also helps many people shed weight.

“ But most attention is focused on dozens Acomplia (rimonabant)  of novel molecules further back in the pipeline,” the Post reports. “There are compounds that block a hormone called ghrelin, which the stomach sends to the brain to rev up an appetite, and agents that mimic another hormone, called PYY, that the gut uses to signal that chow time is over. There are drugs that could prevent a belly full of food from being converted into flab, and others that might act as a workout-in-a-pill by firing up the body’s natural fat-burning systems.”

While many drugs are showing promise, The Post reports that experts say it remains unlikely a single potent agent will be found to cure obesity Acomplia (rimonabant) , given the multiple metabolic signals that humans have evolved to prevent starvation.

“ It may take a few years to shake out, but many experts say at least a handful of safe and effective agents probably will emerge, transforming obesity therapy in the same way cholesterol and blood pressure drugs revolutionized the treatment of heart disease.,” the Post said Acomplia (rimonabant) .

Acomplia (rimonabant) “As we get more and more drugs in this area, we’ll hopefully get better at managing obesity,” said Louis J. Aronne, president-elect of the North American Association for the Study of Obesity. “I think it’s the beginning of a whole new era in the management of obesity.”

Посмотрите также

• Researchers Convinced Variety of Drugs Needed to Beat Body’s Stockpiling of Fat
  A growing number of scientists and doctors have become convinced that overcoming the body’s imperative to stockpile fat will require an Acomplia (rimonabant) assortment of drugs, mixed and matched in various combinations, and that many patients will be taking these cocktails for years — perhaps for life — along with dieting and [...]
• FDA Panel to Weigh Low-Dose Xenical for Over-the-Counter Sale
  The anti-obesity drug Xenical, which never quite lived up to its original hype, may get a new lease on life by becoming the first weight-loss medication to move from prescription to over-the-counter status Acomplia (rimonabant) . GlaxoSmithKline has asked the U.S. Food and Drug Administration for permission to sell a [...]
• Drug treatments for obesity may not be far off — but don’t expect one prescription to fit all
  Doctors used to joke that the best Acomplia (rimonabant)  way to combat obesity was to build up your biceps … in order to push yourself away from the table. Then came the discovery in 1995 of genes that regulate leptin, the hormone that controls how much fat your body stores. Since then, [...]
• Zimulti Acomplia News — Oct. 2007 — News About Rimonabant
  Diet Drug Taranabant Yields Encouraging Results With ‘Generally Mild’ Side-Effects Taranabant, which a year from now may have surged past (Acomplia) rimonabant as the world’s most eagerly awaited diet drug, made a low-key debut Oct. 24th when researchers reported that participants in a clinical trial achieved encouraging weight loss with [...]
• Targeting Peripheral CB1 Receptors May Avoid Acomplia (Rimonabant, Zimulti)
  A diet drug Acomplia (Rimonabant, Zimulti) that selectively targets peripheral CB1 receptors such as those in the liver, instead of targeting all the body’s CB1 receptors including those in the brain like Acomplia (Rimonabant, Zimulti) , may help patients lose weight and lower cardiometabolic risk factors without [...]
• Smoking Rimonabant
  Smoking Rimonabant On March 9, at the American College of Cardiology Scientific Sessions in New Orleans, investigators presented details of their studies with rimonabant (trade name: Acomplia) - the first of a new class of drugs (selective CB1 blockers) aimed at helping with weight loss and smoking cessation. CB1 blockers act on [...]

If you enjoyed this post, please consider to leave a comment or subscribe to the feed and get future articles delivered to your feed reader.

Powered by "ocomplia"
Copyright 2007. News Acomplia Zimulti. All rights reserved

• Home
• Sitemap